Stem cell-based implants successfully secrete insulin in patients with type 1 diabetes
Date:
December 2, 2021
Source:
Cell Press
Summary:
Interim results from a multicenter clinical trial demonstrate insulin secretion from engrafted cells in patients with type 1 diabetes. The safety, tolerability, and efficacy of the implants, which consisted of pancreatic endoderm cells derived from human pluripotent stem cells (PSCs), were tested in 26 patients. While the insulin secreted by the implants did not have clinical effects in the patients, the data are the first reported evidence of meal-regulated insulin secretion by differentiated stem cells in human patients.
Stem Cells therapy
Stem Cell-Based Therapies: A Novel Frontier in Osteoporosis Treatment
**Stem Cell-Based Therapies for Osteoporosis: Exploring Novel Treatment Options** Osteoporosis, a debilitating condition characterized by bone loss and increased fracture risk, poses a significant healthcare burden worldwide. Stem cell-based approaches have emerged as promising therapeutic strategies to address this unmet medical need. Researchers are investigating the potential of stem cells to regenerate bone tissue, enhance bone formation, and modulate immune responses in osteoporosis. This article provides an in-depth analysis of the current state of stem cell-based therapies for osteoporosis, discussing the various types of stem cells, their mechanisms of action, and the challenges and opportunities associated with their clinical translation.